Product Images Aliskiren

This document provides a list of drugs with the potential to interact with aliskiren, including inhibitors of the CYP3A4/P-gp enzymes, antihypertensive agents, and other medications such as statins and digoxin. The table shows the fold change and 90% confidence interval for the impact of co-administered drugs on the pharmacokinetics of aliskiren. Recommendations for each drug either suggest avoiding concomitant use or indicate no need for dose adjustment.*

This document provides information on the impact of aliskiren on the pharmacokinetics of co-administered drugs through fold change and 90% CI. The drugs evaluated include antihypertensives, digoxin, metformin, atorvastatin, lovastatin, celecoxib, and warfarin. Based on the results, no dose adjustment is recommended for any of the drugs.*

This is a medication containing Aliskiren Hemifumarate 165.765 mg, which is equivalent to Aliskiren 150 mg, in each coated tablet. Dosage instructions can be found in the package insert. It should be stored in a tightly closed container at 20° to 25°C to protect against moisture. The medication should be kept out the reach of children. The product is manufactured by Par Formulations Private Limited at a facility in India and distributed in the US by Par Pharmaceutical. The NDC number is 49884-424-11, and it comes in a package of 30 tablets.*

This is a prescription drug with NDC code 49884-425-11. It contains 300mg of Aliskiren Hemifumarate equivalent to Aliskiren 300mg per film-coated tablet. It comes in a package of 30 tablets and is manufactured by Par Formulations Private Limited in India. The recommended dosage should be obtained from the package insert. It should be stored in a tightly closed container at 20°C to 25°C and protected from moisture. The drug should also be kept out of reach of children.*